Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125239 · ClinicalTrials.gov registry record · Phase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Jacqueline Garcia, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03125239 is a Phase 1 study that has completed, run by Jacqueline Garcia, MD. The registered enrollment target is 16 participants.
The verdict
NCT03125239, a Phase 1 study, has completed, sponsored by Jacqueline Garcia, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This research study is studying a combination of two targeted therapies as a possible treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did not fully respond. The name of the study interventions involved in this study are: * Merestinib * LY2874455
Interventions
- DRUG Merestinib
- DRUG LY2874455
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03125239
The ClinicalTrials.gov registry entry for NCT03125239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jacqueline Garcia, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Merestinib is the first listed.
NCT03125239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03125239 about?
NCT03125239 is a clinical study titled "Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia". This research study is studying a combination of two targeted therapies as a possible treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did not fully respond. The name of the study interventions involved in this study are: * Merestinib * LY2874455
What is the current status of trial NCT03125239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-08-10. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03125239?
The interventions under investigation include: Merestinib (DRUG), LY2874455 (DRUG).
Who is sponsoring clinical trial NCT03125239?
This trial is sponsored by Jacqueline Garcia, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.